JP2017524366A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017524366A5 JP2017524366A5 JP2017507848A JP2017507848A JP2017524366A5 JP 2017524366 A5 JP2017524366 A5 JP 2017524366A5 JP 2017507848 A JP2017507848 A JP 2017507848A JP 2017507848 A JP2017507848 A JP 2017507848A JP 2017524366 A5 JP2017524366 A5 JP 2017524366A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- factor
- furin
- transformed
- transformed cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013604 expression vector Substances 0.000 claims 10
- 102000004169 proteins and genes Human genes 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 239000012228 culture supernatant Substances 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 101001022148 Homo sapiens Furin Proteins 0.000 claims 8
- 108010014173 Factor X Proteins 0.000 claims 7
- 108090001126 Furin Proteins 0.000 claims 6
- 102000004961 Furin Human genes 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 3
- 102100022641 Coagulation factor IX Human genes 0.000 claims 2
- 108010076282 Factor IX Proteins 0.000 claims 2
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 claims 2
- 101800004937 Protein C Proteins 0.000 claims 2
- 102000017975 Protein C Human genes 0.000 claims 2
- 229940096437 Protein S Drugs 0.000 claims 2
- 108010066124 Protein S Proteins 0.000 claims 2
- 102000029301 Protein S Human genes 0.000 claims 2
- 108010094028 Prothrombin Proteins 0.000 claims 2
- 101800001700 Saposin-D Proteins 0.000 claims 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 229960004222 factor ix Drugs 0.000 claims 2
- 229940012426 factor x Drugs 0.000 claims 2
- 108010025221 plasma protein Z Proteins 0.000 claims 2
- 229960000856 protein c Drugs 0.000 claims 2
- 108010047303 von Willebrand Factor Proteins 0.000 claims 2
- 102100036537 von Willebrand factor Human genes 0.000 claims 2
- 229960001134 von willebrand factor Drugs 0.000 claims 2
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462036438P | 2014-08-12 | 2014-08-12 | |
| US62/036,438 | 2014-08-12 | ||
| PCT/US2015/044883 WO2016025615A1 (en) | 2014-08-12 | 2015-08-12 | Production of fully processed and functional factor x in a furin-secreting mammalian expression system |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017524366A JP2017524366A (ja) | 2017-08-31 |
| JP2017524366A5 true JP2017524366A5 (enExample) | 2018-09-27 |
| JP6793114B2 JP6793114B2 (ja) | 2020-12-09 |
Family
ID=54035298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017507848A Active JP6793114B2 (ja) | 2014-08-12 | 2015-08-12 | フューリンを分泌する哺乳動物の発現系における、完全に処理され機能的な第x因子の産生 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9873892B2 (enExample) |
| EP (1) | EP3180427B1 (enExample) |
| JP (1) | JP6793114B2 (enExample) |
| CN (1) | CN107002041B (enExample) |
| AR (1) | AR102048A1 (enExample) |
| AU (1) | AU2015301726B2 (enExample) |
| CA (1) | CA2958056C (enExample) |
| EA (1) | EA035444B1 (enExample) |
| ES (1) | ES2742724T3 (enExample) |
| IL (1) | IL250530B (enExample) |
| MX (1) | MX377236B (enExample) |
| NZ (1) | NZ729729A (enExample) |
| TW (1) | TWI666319B (enExample) |
| WO (1) | WO2016025615A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8241623B1 (en) | 2009-02-09 | 2012-08-14 | David Bermudes | Protease sensitivity expression system |
| SG11201912962RA (en) | 2017-06-23 | 2020-01-30 | Baxalta Inc | Purification of factor viii subspecies |
| WO2020257942A1 (en) * | 2019-06-28 | 2020-12-30 | Peel Sean A F | A method for increasing yields and the specific activity of certain recombinant proteins in mammalian cells by co-expressing full-length furin |
| GB202018320D0 (en) * | 2020-11-20 | 2021-01-06 | Univ Newcastle | Methods of producing recombinant complement proteins |
| CN115298204B (zh) * | 2022-01-25 | 2023-04-25 | 青岛万明赛伯药业有限公司 | proNGF突变体及其用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4236698B2 (ja) | 1990-11-26 | 2009-03-11 | ジェネティックス インスティチュート,リミテッド ライアビリティ カンパニー | 宿主細胞でのpaceの発現およびその使用法 |
| AT404838B (de) * | 1995-11-24 | 1999-03-25 | Immuno Ag | Herstellung von proteinen aus pro-proteinen durch fusionsproteine abgeleitet von furin oder furinanalogen |
| JPH09295945A (ja) * | 1996-04-30 | 1997-11-18 | Hoechst Yakuhin Kogyo Kk | 成熟型骨誘導因子の製造方法 |
| US5876923A (en) | 1996-07-26 | 1999-03-02 | Arch Development Corporation | Herpes simplex virus ICP4 as an inhibitor of apoptosis |
| EP1233986A4 (en) | 1999-11-12 | 2003-01-02 | Baxter Biotech Tech Sarl | HEMOGLOBIN COMPOSITIONS WITH REDUCED SIDE EFFECTS |
| US6596526B1 (en) * | 2000-06-09 | 2003-07-22 | Baxter Aktiengesellschaft | Furin polypeptides with improved characteristics |
| EP1622928A4 (en) * | 2003-05-09 | 2006-06-14 | Res Dev Foundation | INSERTION OF FURINE PROTEASE CLEAVAGE SITES IN MEMBRANE PROTEINS AND USES THEREOF |
| PL1969127T5 (pl) * | 2005-12-21 | 2018-02-28 | Cnj Holdings, Inc | Metoda wytwarzania biologicznie czynnych białek zależnych od witaminy K metodami rekombinacji |
| JP5053435B2 (ja) * | 2007-05-18 | 2012-10-17 | バクスター・インターナショナル・インコーポレイテッド | Vwfプロペプチドから成熟vwfを産生するための方法。 |
| CA2710260C (en) * | 2007-12-31 | 2023-07-11 | Barbara Plaimauer | Substantially animal protein-free recombinant furin and methods for producing same |
| KR101544245B1 (ko) | 2009-02-03 | 2015-08-12 | 아뮤닉스 오퍼레이팅 인코포레이티드 | 연장된 재조합 폴리펩티드 및 이를 포함하는 조성물 |
| RU2610436C2 (ru) * | 2011-06-02 | 2017-02-10 | Баксалта Инкорпорейтед | Составы рекомбинантного фурина |
-
2015
- 2015-08-11 AR ARP150102587A patent/AR102048A1/es unknown
- 2015-08-11 TW TW104126066A patent/TWI666319B/zh active
- 2015-08-12 CN CN201580055246.1A patent/CN107002041B/zh active Active
- 2015-08-12 ES ES15757369T patent/ES2742724T3/es active Active
- 2015-08-12 US US14/824,927 patent/US9873892B2/en active Active
- 2015-08-12 AU AU2015301726A patent/AU2015301726B2/en active Active
- 2015-08-12 CA CA2958056A patent/CA2958056C/en active Active
- 2015-08-12 EA EA201790360A patent/EA035444B1/ru not_active IP Right Cessation
- 2015-08-12 EP EP15757369.2A patent/EP3180427B1/en active Active
- 2015-08-12 MX MX2017001931A patent/MX377236B/es active IP Right Grant
- 2015-08-12 WO PCT/US2015/044883 patent/WO2016025615A1/en not_active Ceased
- 2015-08-12 NZ NZ729729A patent/NZ729729A/en unknown
- 2015-08-12 JP JP2017507848A patent/JP6793114B2/ja active Active
-
2017
- 2017-02-09 IL IL250530A patent/IL250530B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR124871A2 (es) | Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes | |
| PH12020551039A1 (en) | Non-viral dna vectors and uses thereof for antibody and fusion protein production | |
| IL259120A (en) | Her2-targeted antigen chimeric receptors2 | |
| FI3536797T3 (fi) | Siirtogeenin tehostettu ilmentäminen ja prosessointi | |
| JP2017524366A5 (enExample) | ||
| MX2020000244A (es) | Vectores virales recombinantes con tropismo modificado y usos de estos para la introduccion dirigida de material genetico a celulas humanas. | |
| WO2016092550A3 (en) | Methods of producing long acting ctp-modified polypeptides | |
| NZ751946A (en) | Rna-guided nucleic acid modifying enzymes and methods of use thereof | |
| EA201492202A1 (ru) | Способ экспрессии гетерологичных белков с использованием рекомбинантного вирусного вектора с минус-нитью рнк | |
| JP2010519251A5 (enExample) | ||
| MX384960B (es) | Cultivo celular metabolicamente optimizado | |
| MY205245A (en) | Scalable method for producing recombinant adeno-associated viral (aav) vector in serum-free suspension cell culture system suitable for clinical use | |
| IL292650B1 (en) | COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Ra2 | |
| HK1214739A1 (zh) | 工程化的分泌蛋白质和方法 | |
| EA201692359A1 (ru) | Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса | |
| JP2010518833A5 (enExample) | ||
| SG10201809152QA (en) | Recombinant host cell for expressing proteins of interest | |
| SG10201809146QA (en) | Recombinant host cell engineered to overexpress helper proteins | |
| JP2016105737A5 (enExample) | ||
| ATE481483T1 (de) | Verfahren zur herstellung eines rekombinanten polyklonalen proteins | |
| IN2014DN03419A (enExample) | ||
| WO2011091350A3 (en) | Methods & compositions for improving protein production | |
| JP2020509751A5 (enExample) | ||
| WO2020047467A3 (en) | Cardiac cell reprogramming with myocardin and ascl1 | |
| JP2019514399A5 (enExample) |